Piribedil dihydrochloride 是一种有效且具有口服活性的多巴胺 D2 (dopamine D2) 和 多巴胺 D3 (dopamine D3) 激动剂。Piribedil dihydrochloride 也是一种 α2-肾上腺素受体 (α2-adrenoceptors) 拮抗剂。Piribedil dihydrochloride 可抑制 MLL1 甲基转移酶的活性 (EC50: 0.18 μM)。Piribedil dihydrochloride 可用于研究帕金森病,循环系统疾病,癌症。
生物活性 | Piribedil dihydrochloride is a potent and orally activedopamine D2anddopamine D3agonist. Piribedil dihydrochloride is also aα2-adrenoceptorsantagonist. Piribedil dihydrochloride can inhibitMLL1methyltransferase activity (EC50: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4]. |
IC50& Target[1] | |
体外研究 (In Vitro) | Piribedil dihydrochloride (0-160 μM, 7 days) specifically inhibits MLL1 methyltransferase activity and selectively suppresses MLL-r cell proliferation[4]. Piribedil dihydrochloride (0-160 μM, 4 days) selectively decreases the H3K4 methylation in MLL-r cells (THP-1 and MV4;11), by disturbing the MLL1-WDR5 interaction[4]. Piribedil dihydrochloride (0-160 μM, 4 days) induces cell-cycle arrest, apoptosis and differentiation in MLL-r cells (THP-1 and MV4;11)[4].
Cell Viability Assay[4] Cell Line: | MLL-r AML cells (THP-1 and MV4;11), non-MLL leukemia cell line (K562) | Concentration: | 0, 20, 40, 80 and 160 μM | Incubation Time: | 0-7 days | Result: | Inhibited the growth rate of the THP-1 and MV4;11 cells in a time-dependent manner. |
Western Blot Analysis[4] Cell Line: | THP-1 and MV4;11 cells | Concentration: | 0, 20, 40, 80 and 160 μM | Incubation Time: | 4 days | Result: | Decreased the levels of H3K4me2 and H3K4me3 without affecting the methylation of other histones, such as H3K79, H3K36 and H3K27. |
|
体内研究 (In Vivo) | Piribedil dihydrochloride (intraperitoneal injection, 5, 15, 40 mg/kg ) alleviates the L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease[2]. Piribedil dihydrochloride (oral gavage, 4-5 mg/kg, daily for 2 weeks) increases locomotor activity and reversal of motor deficits in adult common marmosets[3]. Piribedil dihydrochloride (oral gavage, 150 mg/kg, daily for 21 days) inhibits MLL-r tumor growth and decreases the expression of MLL1 target genes in MV4;11 tumor xenografts[4].
Animal Model: | Rat model of Parkinson’s disease[2] | Dosage: | 5, 15, 40 mg/kg | Administration: | Intraperitoneal injection, administered 5 min before administration of L-DOPA. | Result: | Reduced turning behaviour and AD (axial dystonia), OD (orolingual dyskinesia) and FD (forelimb dyskinesia) at 5 and 40 mg/kg. Increased LD (locomotive dyskinesias) at the 40 mg/kg. |
Animal Model: | Adult common marmosets[3] | Dosage: | 4-5 mg/kg | Administration: | Oral gavage, daily for 2 weeks | Result: | Increased vigilance and alertness and reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum. |
|
Clinical Trial | |
分子量 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |